| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Specialized Center of Research in Hypertension Genetics, Department of Internal Medicine, and General Clinical Research Center, University of Iowa, Iowa City, Iowa 52242
Obesity is associated with increased cardiovascular morbidity and mortality, in part through development of hypertension. Recent observations suggest that the cardiovascular actions of leptin may help explain the link between excess fat mass and cardiovascular diseases. Leptin is an adipocyte-derived hormone that acts in the central nervous system to promote weight loss by decreasing food intake and increasing metabolic rate. Leptin causes a significant increase in overall sympathetic nervous activity, which appears to be due to direct hypothalamic effects and is mediated by neuropeptide systems such as the melanocortin system and corticotropin-releasing hormone. Renal sympathoactivation to leptin is preserved in the presence of obesity, despite resistance to the metabolic effects of leptin. Such selective leptin resistance, in the context of circulating hyperleptinemia, could predispose to obesity-related hypertension. Some in vitro studies have suggested that leptin may have peripheral actions such as endothelium-mediated vasodilation that might oppose sympathetically induced vasoconstriction. However, we and others have shown that leptin does not have direct vasodilator effects in vivo. The fact that chronic leptin administration or overexpression of leptin produces hypertension supports the concept that the hemodynamic actions of leptin are due predominantly to sympathetic activation. Exploration of the sites and mechanisms of leptin resistance should provide novel therapeutic strategies for obesity, insulin resistance, and hypertension.
This article has been cited by other articles:
![]() |
E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Yang and L. A. Barouch Leptin Signaling and Obesity: Cardiovascular Consequences Circ. Res., September 14, 2007; 101(6): 545 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Madani, S. De Girolamo, D. M. Munoz, R.-K. Li, and G. Sweeney Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes Cardiovasc Res, February 15, 2006; 69(3): 716 - 725. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J Morris, E. Velkoska, and T. J Cole Central and peripheral contributions to obesity-associated hypertension: impact of early overnourishment Exp Physiol, September 1, 2005; 90(5): 697 - 702. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Knudson, U. D. Dincer, G. M. Dick, H. Shibata, R. Akahane, M. Saito, and J. D. Tune Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1038 - H1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. Hunt, E. W. Hogeland, M. K. Henry, and S. J. Swoap Hypotension and bradycardia during caloric restriction in mice are independent of salt balance and do not require ANP receptor Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1446 - H1451. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |